Mesoblast (MESO) Cash from Operations (2014 - 2023)
Mesoblast (MESO) posted Cash from Operations of 16278000.0 for Q2 2023, little changed sequentially from 16250000.0 in Q1 2023, and down 17.16% YoY from 19649568.38 in Q2 2022.
Analysis
Mesoblast (MESO) Cash from Operations (2014 - 2023) Analysis & Trends
Mesoblast has reported Cash from Operations for 8 years, with the latest figure at 16278000.0 in Q2 2023.
- Quarterly Cash from Operations fell 17.16% year-over-year to 16278000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 63269000.0 (up 3.82% YoY) and the FY2025 annual result came in at 50000000.0, down 3.18% from the prior year.
- Cash from Operations was little changed at 16278000.0 in Q2 2023 per MESO's latest filing, from 16250000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1330000.0 in Q4 2019 and troughed at 30580000.0 in Q4 2020.
- A 5-year average of 17882333.33 and a median of 17326500.0 in 2021 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2020 and 2021: Cash from Operations plunged 2199.25% in 2020, then surged 40.42% in 2021.
- Over 5 years, Cash from Operations stood at 1330000.0 in 2019, then slumped by 2199.25% to 30580000.0 in 2020, then surged by 40.42% to 18219000.0 in 2021, then climbed by 9.69% to 16454000.0 in 2022, then increased by 1.07% to 16278000.0 in 2023.
- According to Business Quant data, Cash from Operations over the past three periods registered 16278000.0, 16250000.0, and 16454000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 110.26 Mn |
| Mar 31, 2023 | -77.73 Mn |
| Dec 31, 2022 | 16.45 Mn |
| Sep 30, 2022 | 14.29 Mn |
| Jun 30, 2022 | -13.89 Mn |
| Mar 31, 2022 | -15.47 Mn |
| Dec 31, 2021 | -18.22 Mn |
| Sep 30, 2021 | 18.20 Mn |
| Jun 30, 2021 | -18.92 Mn |
| Mar 31, 2021 | -24.47 Mn |
| Dec 31, 2020 | -30.58 Mn |
| Sep 30, 2020 | -28.17 Mn |
| Mar 31, 2020 | -36.78 Mn |
| Dec 31, 2019 | -16.89 Mn |
| Sep 30, 2019 | -15.56 Mn |
| Mar 31, 2019 | -21.19 Mn |
| Dec 31, 2018 | -1.96 Mn |
| Sep 30, 2018 | -19.54 Mn |
| Jun 30, 2018 | -20.19 Mn |
| Mar 31, 2018 | -19.60 Mn |